Prednisone inhibits the IL-1β-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity

Hong,Hua; Jang,Byeong-Churl

doi:10.3892/ijmm.2014.1967

Prednisone inhibits the IL-1β-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity

Authors:
- Hua Hong
- Byeong-Churl Jang
View Affiliations

Affiliations: Department of Molecular Medicine, College of Medicine, Keimyung University, Dalseo-gu, Daegu 704-701, Republic of Korea
Published online on: October 14, 2014 https://doi.org/10.3892/ijmm.2014.1967
Pages: 1640-1646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hearing loss can be induced by multiple causes, including cochlear inflammation. Prednisone (PDN) is a well‑known steroid clinically used in the treatment of hearing loss. In the present study, we investigated the inhibitory effects and the mechanisms of action of PDN on the expression of cyclooxygenase (COX)-2, an inflammatory enzyme involved in the production of prostaglandins (PGs), in House Ear Institute-Organ of Corti 1 (HEI‑OC1) cells (a murine auditory cell line) treated with the inflammatory cytokine, interleukin (IL)-1β. The exposure of HEI-OC1 cells to IL-1β increased COX-2 protein and mRNA expression, COX-2 promoter-driven luciferase activity and COX-2 enzymatic activity [as indicated by the increased production of prostaglandin E2 (PGE2), a major COX-2 metabolite]. However, PDN markedly inhibited the IL-1β-induced COX-2 protein and mRNA expression, COX-2 promoter activity and PGE2 production in the HEI-OC1 cells without affecting COX-2 protein and mRNA stability. PDN further inhibited the IL-1β-induced activation of extracellular signal-regulated kinase (ERK)-1/2 and c-Jun N-terminal kinase (JNK)-1, but had no effect on the cytokine‑induced activation of p38 MAPK and proteolysis of IκB-α, a nuclear factor-κB (NF-κB) inhibitory protein. PDN also partially suppressed the IL-1β‑induced activation of activator protein (AP)-1 (but not that of NF-κB) promoter-driven luciferase activity. Of note, the inhibitory effects of PDN on the IL-1β-induced expression of COX-2 and the activation of ERK-1/2 and JNK-1 in the HEI-OC1 cells were significantly diminished by RU486, a glucocorticoid receptor (GR) antagonist, suggesting that PDN exerts its inhibitory effects through GR. To the best of our knowledge, our study demonstrates for the first time that PDN inhibits the IL-1β-induced COX-2 expression and activity in HEI-OC1 cells by COX-2 transcriptional repression, which is partly associated with the inhibition of ERK-1/2, JNK-1 and AP-1 activation.

View Figures

View References

1	World Health Organization. Epidemic meningococcal disease. WHO fact sheet. (105)1998.
2	Schuchat A, Robinson K, Wenger JD, et al: Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 337:970–976. 1997. View Article : Google Scholar : PubMed/NCBI
3	Davis AC: Epidemiological profile of hearing impairments: the scale and nature of the problem with special reference to the elderly. Acta Otolaryngol Suppl. 476:23–31. 1990.PubMed/NCBI
4	Ries PW: Prevalence and characteristics of persons with hearing trouble: United States, 1990–91. Vital Health Stat. 188:1–75. 1994.PubMed/NCBI
5	Satoh H, Firestein GS, Billings PB, Harris JP and Keithley EM: Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J Assoc Res Otolaryngol. 4:139–147. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wakabayashi K, Fujioka M, Kanzaki S, et al: Blockade of interleukin-6 signaling suppressed cochlear inflammatory response and improved hearing impairment in noise-damaged mice cochlea. Neurosci Res. 66:345–352. 2010. View Article : Google Scholar : PubMed/NCBI
7	Matz G: Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am. 26:705–712. 1993.PubMed/NCBI
8	Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
9	Smith WL and DeWitt DL: Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 62:167–215. 1996. View Article : Google Scholar
10	Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120. 1998. View Article : Google Scholar
11	Feng L, Sun W, Xia Y, et al: Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys. 307:361–368. 1993. View Article : Google Scholar : PubMed/NCBI
12	Cho JW, Park K, Kweon GR, et al: Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med. 37:186–192. 2005. View Article : Google Scholar : PubMed/NCBI
13	Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky P: Cyclooxygenase in biology and disease. FASEB J. 12:1063–1073. 1998.PubMed/NCBI
14	Stjernschantz J, Wentzel P and Rask-Andersen H: Localization of prostanoid receptors and cyclo-oxygenase enzymes in guinea pig and human cochlea. Hear Res. 197:65–73. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ziegler EA, Brieger J, Heinrich UR and Mann WJ: Immuno-histochemical localization of cyclooxygenase isoforms in the organ of Corti and the spiral ganglion cells of guinea pig cochlea. ORL J Otorhinolaryngol Relat Spec. 66:297–301. 2004. View Article : Google Scholar : PubMed/NCBI
16	Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H and Baerwald CG: Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol. 35:979–985. 2008.PubMed/NCBI
17	Barnes PJ and Adcock IM: How do corticosteroids work in asthma? Ann Intern Med. 139:359–370. 2003. View Article : Google Scholar : PubMed/NCBI
18	Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA and Baldwin AS Jr: Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 15:943–953. 1995.PubMed/NCBI
19	De Bosscher K, Beck IM, Dejager L, et al: Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1. Cell Mol Life Sci. 71:143–163. 2014.PubMed/NCBI
20	Langlais D, Couture C, Balsalobre A and Drouin J: The Stat3/GR interaction code: predictive value of direct/indirect DNA recruitment for transcription outcome. Mol Cell. 47:38–49. 2012.PubMed/NCBI
21	Adcock IM: Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther. 14:211–219. 2001. View Article : Google Scholar : PubMed/NCBI
22	Kalinec GM, Webster P, Lim DJ and Kalinec F: A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol Neurootol. 8:177–189. 2003. View Article : Google Scholar : PubMed/NCBI
23	Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K and Okano H: Proinflammatory cytokines expression in noise-induced damaged cochlea. J Neurosci Res. 83:575–583. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ghaheri BA, Kempton JB, Pillers DA and Trune DR: Cochlear cytokine gene expression in murine acute otitis media. Laryngoscope. 117:22–29. 2007. View Article : Google Scholar : PubMed/NCBI
25	Herschman HR, Reddy ST and Xie W: Function and regulation of prostaglandin synthase-2. Adv Exp Med Biol. 407:61–66. 1997. View Article : Google Scholar : PubMed/NCBI
26	Inoue H, Yokoyama C, Hara S, Tone Y and Tanabe T: Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem. 270:24965–24971. 1995. View Article : Google Scholar
27	Inoue H and Tanabe T: Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem Biophys Res Commun. 244:143–148. 1998. View Article : Google Scholar : PubMed/NCBI
28	Ghosh S and Baltimore D: Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 344:678–682. 1990. View Article : Google Scholar : PubMed/NCBI
29	Newton R, Kuitert LM, Bergmann M, Adcock IM and Barnes PJ: Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem and Biophys Res Commun. 237:28–32. 1997. View Article : Google Scholar : PubMed/NCBI
30	Jang BC, Paik JH, Kim SP, et al: Catalase induced expression of inflammatory mediators via activation of NF-κB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal. 17:625–633. 2005.
31	Allport VC, Slater DM, Newton R and Bennett PR: NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod. 6:561–565. 2000. View Article : Google Scholar : PubMed/NCBI
32	Benkoussa M, Brand C, Delmotte MH, Formstecher P and Lefebvre P: Retinoic acid receptors inhibit AP1 activation by regulating extracellular signalregulated kinase and CBP recruitment to an AP1-responsive promoter. Mol Cell Biol. 22:4522–4534. 2002. View Article : Google Scholar : PubMed/NCBI
33	Caelles C, Gonzalez-Sancho JM and Munoz A: Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11:3351–3364. 1997. View Article : Google Scholar : PubMed/NCBI
34	Newton R, Stevens DA, Hart LA, Lindsay M, Adcock IM and Barnes PJ: Super-induction of COX-2 mRNA by cyclohexamide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett. 418:135–138. 1997. View Article : Google Scholar : PubMed/NCBI
35	Jang BC, Sung SH, Park JG, et al: Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem. 282:27622–27632. 2007. View Article : Google Scholar
36	Nam SI: Interleukin-1beta up-regulates inducible nitric oxide by way of phosphoinositide 3-kinase-dependent in a cochlear cell model. Laryngoscope. 116:2166–2170. 2006. View Article : Google Scholar : PubMed/NCBI
37	Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 148:245–254. 2006. View Article : Google Scholar : PubMed/NCBI
38	Bailey JM: New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors. 3:97–102. 1991.PubMed/NCBI
39	Herr BD and Marzo SJ: Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 132:527–531. 2005. View Article : Google Scholar : PubMed/NCBI
40	De Bosscher K, Van Craenenbroeck K, Meijer OC and Haegeman G: Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol. 583:290–302. 2008.PubMed/NCBI
41	Newton R and Holden NS: Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 72:799–809. 2007. View Article : Google Scholar : PubMed/NCBI
42	Ristimaki A, Garfinkel S, Wessendorf J, Maciag T and Hla T: Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem. 269:11769–11775. 1994.PubMed/NCBI
43	Jang BC, Sanchez T, Schaefers HJ, et al: Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem. 275:39507–39515. 2000. View Article : Google Scholar
44	Park YK, Hong H and Jang BC: Transcriptional and translational regulation of COX-2 expression by cadmium in C6 glioma cells. Int J Mol Med. 30:960–966. 2012.PubMed/NCBI